Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Pasithea Therapeutics Corp ( (KTTA) ) just unveiled an announcement.
On May 6, 2025, Pasithea Therapeutics Corp. entered into securities purchase agreements to sell shares of common stock and warrants, raising approximately $6.3 million in gross proceeds. The company plans to use the net proceeds of $4.3 million for general corporate purposes, including research, clinical trials, and potential acquisitions. The offering closed on May 7, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on discovering, researching, and developing innovative treatments for central nervous system disorders, RASopathies, and MAPK pathway-driven tumors.
Average Trading Volume: 5,612,569
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.